Will Options Traders' Surge in Centessa After Eli Lilly Buyout Confirmation Fuel a Pipeline Rally?
Schaeffer's Research lit up trading screens this week, spotlighting a pharma stock flooded with options action right after Eli Lilly confirmed its blockbuster buyout of Centessa Pharmaceuticals (CNTA). Traders piled into calls on CNTA, signaling bets on further upside as the $7.8 billion deal—previously valued around $6.3-$7.8 billion in analyst chatter—progresses toward closing. CNTA shares exploded +43.6% to $39.61 on March 31, 2026, on blockbuster volume of 44.5 million shares, dwarfing its prior daily average.
This isn't just tender-offer froth. The options frenzy underscores investor conviction that Centessa's orexin-targeted sleep disorder assets—headlined by ORX750—could slot seamlessly into Lilly's obesity and neuroscience juggernaut, already firing on Mounjaro and Zepbound cylinders. With the deal's closing now in sight, the question is whether this validates Lilly's (LLY) aggressive M&A spree or risks diluting its pristine growth story.
Centessa's Explosive Reaction: Deal Premium and Options Heat
CNTA's chart tells the tale. Shares traded sideways around $23-$28 through early March 2026 before ramping into the $28-$29 zone. Then, boom: the March 31 confirmation sent it vertical, hitting $39.61 intraday amid the highest volume in years (44.5M shares vs. typical 1-2M). That's a 13% 1-month gain pre-spike, accelerating to 43.6% daily on the news.
| Metric | CNTA Pre-Announcement (Mar 27) | Post-Confirmation (Mar 31) | Change |
|---|---|---|---|
| Adj Close | $28.70 | $39.61 | +38.1% |
| Volume | 1.4M | 44.5M | +3,100% |
| 1M Return | +13.4% | N/A | N/A |
| 3M Return | +13.3% | N/A | N/A |
Schaeffer's call-buying surge—unusually bullish for a takeover target—hints at speculation on deal sweeteners, regulatory nods, or pipeline pops. Centessa's ORX750, a next-gen orexin receptor 2 agonist, targets orexin neuron loss in hypersomnolence disorders, a $5B+ TAM ripe for disruption. Phase 1 data showed clean safety and orexin-appropriate effects; Phase 2 readouts loom in 2026, potentially syncing with Lilly's incretin dominance.
Contrast this with LLY's steadier grind. The pharma titan dipped -5.1% over 3 months to $918.95, but that's noise amid $868 billion market cap. 1-day: +3.6%; 1-month: -4.6%. Options flow in CNTA could foreshadow LLY sympathy if synergies crystallize post-close.
Lilly's M&A Machine: Centessa Fits the Obesity/Neuro Template
Eli Lilly isn't shopping impulsively. 2025's 10-K (filed Feb 2026) brags $3B in acquired IPR&D, including Scorpion's PI3Kα inhibitor and SiteOne—echoing Centessa's profile. Pending deals total <$3B, but Centessa's $5.3B mcap at current prices suggests a premium tender (likely $40+/share based on spike).
Lilly's war chest? $7.3B cash (up from $3.3B in 2024), $16.8B operating cash flow. Debt at $42.5B (up $8.9B YoY), but net debt/EBITDA comfy amid 45% revenue growth to $65.2B in 2025. Non-GAAP margins hit 46-47.5% guidance for 2026, with revenue eyed at $80-83B (+25% midpoint).
Centessa bolsters the sleep-obesity nexus. Orexin pathways overlap GLP-1 effects; ORX750 could pair with tirzepatide (SURPASS-CVOT win) for combo therapies. Earnings calls hammer this: Q4 2025 guidance flags orforglipron launch 2026, Medicare obesity access July 2026. Centessa accelerates neuro pipeline beyond Kisunla (Alzheimer's approval).
| Key Metric (TTM) | LLY | CNTA |
|---|---|---|
| Market Cap | $868B | $5.3B |
| P/E TTM | 40.0 | N/A |
| P/E Fwd | 25.3 | N/A |
| Price 1M Return | -4.6% | +13.4% |
| Revenue (2025) | $65.2B | Pre-revenue |
Valuation: Premium Paid, But Synergies Justify?
Skeptics balk at the price tag—$7.8B for a clinical-stage play vs. LLY's P/E fwd 25x. Yet Lilly's track record shines: Morphic, POINT, DICE integrations fueled 32% 2024 revenue growth. Centessa's 134M shares at $39.61 imply $5.3B equity value; add net cash (~$500M from old filings), and it's accretive if ORX750 hits Phase 3.
Risks? Antitrust scrutiny (FTC eyeing pharma M&A), integration hiccups, or Phase 2 flops. LLY's $3B+ annual R&D absorbs this, but dilution looms (943M shares out). Still, fcf margin strength and dividend growth buffer.
Bull case dominates: Options traders aren't wrong. Centessa's orexin edge targets underserved hypersomnia ($2B+ peak sales potential per analysts), stacking with Lilly's $50/month obesity access deal. Post-close, expect pipeline bundling in Q2 2026 calls.
The Trade: Buy LLY Dips, Watch CNTA Tender
Bullish on LLY. The Centessa close—imminent per price action—turbocharges a pipeline already printing $80B+ revenue in 2026. Options heat validates the bet; LLY's 25x fwd P/E discounts execution risks priced out by 45% CAGR. CNTA arb players: pocket the premium.
Monitor: ORX750 Phase 2 data (H2 2026), HSR antitrust clearance, Lilly Q1 earnings (April 2026). Tariffs? Lilly shrugs them off per guidance. This deal isn't transformative—it's incremental firepower for the GLP-1 king.